Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Axillary Hyperhidrosis

In brief

The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.

Key facts

Study ID

NCT01799824

Run by

Anterios Inc.

People needed

52

Starts

2013-02-01

Expected to finish

2013-07-01

Last updated by the study team

2013-12-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ages 18 - 70 years of age
• diagnosis of moderate to severe primary axillary hyperhidrosis
• ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically
• HDSS score of ≥3

You may not qualify if…

• diagnosis of secondary hyperhidrosis
• skin affliction in the axilla requiring medical treatment
• 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline
• oral anticholinergic treatment
• botulinum toxin treatment in the prior 9 months
• history of surgery for axillary hyperhidrosis
• present or history of neuromuscular disease
• female subjects who are pregnant or are nursing a child

Where it is running

• Study site — Miami, Florida, United States
• Study site — Pinellas Park, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Louisville, Kentucky, United States
• Study site — East Windsor, New Jersey, United States
• Study site — Rochester, New York, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Yardley, Pennsylvania, United States
• Study site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.